|
WO2020204117A1
|
|
Pharmaceutical composition having favorable stability
|
|
CN111386109A
|
|
Pharmaceutical composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis
|
|
CN111225637A
|
|
Stent and medical device comprising same
|
|
JP2020012649A
|
|
Weighing system and weighing method
|
|
CN109789120A
|
|
Granular preparation
|
|
JP2018042576A
|
|
Jellied composition
|
|
JP2019112313A
|
|
Medicament composition
|
|
JP2019031449A
|
|
Sulfonamide derivative and pharmaceutical composition containing the same
|
|
JP2018070580A
|
|
Reflux esophagitis recurrence inhibitor
|
|
TW201731824A
|
|
INTEGRIN [alpha]4[beta]7 INHIBITOR
|
|
WO2017135472A1
|
|
Sulfonamide derivative and pharmaceutical composition containing same
|
|
EP3412664A1
|
|
Heterocyclic sulfonamide derivative and medicine containing same
|
|
EP3330266A1
|
|
Cyclopropane derivative and drug containing same
|
|
CN107106572A
|
|
Corneal epithelium treating dysfunction agent
|
|
JP2017075106A
|
|
Tablet, solid dispersion and method for producing the same, magnesium aluminometasilicate and evaluation method therefor
|
|
CA2973542A1
|
|
Enema for rectal application
|
|
US2017143738A1
|
|
Solid formulation and method for stabilizing the same
|
|
CN106458965A
|
|
Method for producing heteroarylcarboxylic acid ester derivative, and production intermediate of same
|
|
CA2938198A1
|
|
Heterocyclic sulfonamide derivative and medicine comprising same
|
|
EP3097912A1
|
|
Megalin antagonist
|
